BioXcel Therapeutics, Inc.
No SEC Form 4 filings for $BTAI in the last 30 days.
See all $BTAI insider activity →BioXcel Therapeutics (BTAI) agreed to sell its assets to Teva Pharmaceuticals and filed for Chapter 11 bankruptcy. The deal includes IGALMI and BXCL501. The company secured $19M in financing and plans to seek higher bids. IGALMI remains available, and BXCL501's FDA decision is due November 14. BTAI stock is down 46.30% pre-market.
BioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 of this Current Report on Form 8-K is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. On August 27, 2026 (the “Petition Date”), BioXcel Therapeutics, Inc. (t
BioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 24, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Fourteenth Amendment to Credit Agreement and Guaranty (the “Fourteenth Amendment”), which amended the Credit Agreement and Guaranty, dated April 1
Over the past 7 days, alphai's AI scored 4 news stories mentioning BTAI (BioXcel Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 2 bearish.
Recent BTAI coverage spans corporate actions and financial news.
Bankruptcy filing and asset sale likely depress BTAI equity sharply, with limited upside until restructuring resolves.
Bankruptcy and asset sale likely depress equity value, but DIP financing and potential sale may provide upside if higher bids emerge.
The amendment provides additional liquidity but reduces covenant thresholds, potentially easing short‑term cash pressure.
Potential refinancing or capital‑raising could affect liquidity and share price.
The 8-K discloses a near-term covenant and refinancing deadline change, which can reduce immediate liquidity pressure but keeps a hard action date (Aug 21, 2026) for an acceptable transaction.
alphai scores every news story that mentions BTAI with an AI model for sentiment and relevance, and aggregates insider trades from BioXcel Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioXcel Therapeutics (BTAI) agreed to sell its assets to Teva Pharmaceuticals and filed for Chapter 11 bankruptcy. The deal includes IGALMI and BXCL501. The company secured $19M in financing and plans to seek higher bids. IGALMI remains available, and BXCL501's FDA decision is due November 14. BTAI stock is down 46.30% pre-market.
2 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 of this Current Report on Form 8-K is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. On August 27, 2026 (the “Petition Date”), BioXcel Therapeutics, Inc. (t
2 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 24, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Fourteenth Amendment to Credit Agreement and Guaranty (the “Fourteenth Amendment”), which amended the Credit Agreement and Guaranty, dated April 1
1 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Thirteenth Amendment to Credit Agreement and Guaranty (the “Thirteenth Amendment”), which amended the Credit Agreement and Guaranty, dated April 1
1 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 10, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Twelfth Amendment to Credit Agreement and Guaranty and First Amendment to Security Agreement (the “Twelfth Amendment”), which amended the Credit A
2 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Eleventh Amendment to Credit Agreement and Guaranty (the “Eleventh Amendment”), which amended the Credit Agreement and Guaranty, dated April 19, 202
6 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2619779d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 TENTH AMENDMENT TO Credit agreement AND guaranty This Tenth Amendment to Credit Agreement and Guaranty (this “ Amendment ”) is made as of July 3, 2026, by and among BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the
4 min readBioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently engaged in equity compensation activities. He exercised 17,500 Restricted Stock Units (RSUs) on May 4, 2026, and subsequently sold 6,845 common shares on May 20, 2026, at a weighted average price of $1.085 per share to cover tax obligations from the RSU vesting. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, and after these transactions, Yocca retains a significant holding of common shares and RSUs.
2 min readBioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently sold 6,845 shares of the company’s common stock for $7,426 to cover taxes related to vested restricted stock units. This transaction, executed under a Rule 10b5-1 trading plan, occurred after he acquired 17,500 shares through RSU vesting earlier in May. Following these events, Yocca directly holds 26,175 shares.
2 min readBioXcel Therapeutics CEO Vimal Mehta reported exercising 49,758 Restricted Stock Units (RSUs) and subsequently selling 19,419 common shares at a weighted average price of $1.087 to cover tax obligations from the RSU vesting. This sale was conducted under a Rule 10b5-1 trading plan. After the transaction, Mehta directly holds 69,598 common shares, with additional indirect holdings through BioXcel LLC and his spouse.
2 min read
